Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Cidara Therapeutics Inc (CDTX) USD0.0001

Sell:$2.16 Buy:$2.37 Change: $0.06 (2.54%)
Market closed |  Prices as at close on 5 March 2021 | Switch to live prices |
Change: $0.06 (2.54%)
Market closed |  Prices as at close on 5 March 2021 | Switch to live prices |
Change: $0.06 (2.54%)
Market closed |  Prices as at close on 5 March 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cidara Therapeutics Inc., is a clinical-stage biotechnology company focused on developing new anti-infectives. The Company’s lead product candidate is rezafungin acetate, which is a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. The Company is also leveraging its novel Cloudbreak platform to develop antibody-drug conjugates for the treatment of serious viral and Gram-negative bacterial infections. Cloudbreak is the immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens.

Contact details

6310 Nancy Ridge Dr Ste 101
United States
+1 (858) 7526170

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$112.42 million
Shares in issue:
48.04 million
United States
US dollar

Key personnel

  • Daniel Burgess
    Independent Chairman of the Board
  • Jeffrey Stein
    President, Chief Executive Officer, Director
  • James Levine
    Chief Financial Officer
  • Paul Daruwala
    Chief Operating Officer
  • Christopher Kurtz
    Executive Vice President of Technical Operations
  • Jessica Oien
    General Counsel, Secretary
  • Neil Abdollahian
    Chief Business Officer
  • Taylor Sandison
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.